CAS: 41994-51-8; 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid Hydrochloride

相似化合物

67123-97-1 103733-65-9 115962-35-1

上下游产品

CAS号50-00-0 甲醛 | CAS号150-30-1 DL-苯丙氨酸 | CAS号63-91-2 L-苯丙氨酸 | CAS号104668-15-7 3-甲酰基-3,4-二氢-1H... | CAS号57060-88-5 1,2,3,4-四氢异喹啉-3... | CAS号143767-54-8 2-乙酰基-1,2,3,4-四... | CAS号243858-66-4 3-(羟甲基)-3,4-二氢异... | CAS号151838-62-9 2-(叔丁氧基羰基)-1,2,... | CAS号112794-29-3 1,2,3,4-四氢异喹啉-3-甲酰胺 | CAS号74618-46-5 dimethyl 3-meth... | CAS号93316-40-6 2-苯甲酰基-1,2,3,4-...

L-苯丙氨酸 反应生成 1,2,3,4-四氢-3-异喹啉羧酸 盐酸盐
参考文献:Retroviral Protease Inhibitors
标题:Retroviral Protease Inhibitors
摘要:本发明提供了新型hiv蛋白酶抑制剂,含有这些化合物的药物配方以及它们的使用方法.

专利信息

专利号:US-8410130-B2
优先权日:2007-11-07
标题 :Synthesis of 8H-3A-aza-cyclopenta [A ]indenes and 5,10-dihydropyrrolo[1,2-B]isoquinolines derivatives and their use as antitumor therapeutic agents
发明人：SU TSANN-LONG; CHOU TING-CHAO
权利人:SU TSANN-LONG; CHOU TING-CHAO; ACADEMIA SINICA
摘要:The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have little or no cross-resistance to either Taxol or Vinblastine. The results demonstrated that compounds disclosed herein possess potent antitumor therapeutic efficacy and are expected to have potential for clinical applications.

专利号:US-11420997-B2
优先权日:2018-04-13
标题:Peptide synthesis method
发明人：SUZUKI HIDEAKI; MUTO SUSUMU; FUJITA SHUJI; KUBO DAISUKE
权利人:JITSUBO CO LTD
摘要:The present invention has an object of shortening the process time and reducing use of a poor solvent for solidifying a carrier (Tag)-peptide component, by removing impurities without conducting solid-liquid separation (condensation, solid-liquid separation and drying operation) of a Tag-peptide component, in an Fmoc method using a Tag for liquid phase peptide synthesis. Provided is the peptide synthesis method that includes the following steps a-d: step a: a carrier-protected amino acid, carrier-protected peptide, or a carrier-protected amino acid amide, and an N-Fmoc-protected amino acid or an N-Fmoc-protected peptide are condensed in an organic solvent or a mixed solution of organic solvents, to obtain an N-Fmoc-carrier-protected peptide, step b: a water-soluble amine is added to the reaction solution after the condensation reaction, step c: the Fmoc group is deprotected from the protected amino group in the presence of a water-soluble amine, and step d: the reaction solution is neutralized by adding an acid, and further, by adding and washing with an acidic aqueous solution, then, by liquid-liquid separation an aqueous layer is removed to obtain an organic layer.

专利号:US-5166394-A
优先权日:1990-05-23
标题 :Coupling reagent for peptide synthesis
发明人：BREIPOHL GERHARD; KOENIG WOLFGANG
权利人:HOECHST AG
摘要:Novel compounds of the formula I ##STR1## in which X is an anion, and a process for the preparation thereof, are described. Compounds of the formula I are used as coupling reagents in peptide synthesis.

专利号:US-2009117125-A1
优先权日:2007-11-07
标 题:Synthesis of 8h-3a-aza-cyclopenta[a]indenes and 5,10-dihydropyrrolo[1,2-b]isoquinolines derivatives and their use as antitumor therapeutic agents

专利号:WO-9807746-A1
优先权日:1996-08-19
标题:B1-bradykinin receptor antagonists and use thereof
发明人：REGOLI DOMENICO; PLANTE GERARD E; GOBEIL FERNAND; NEUGEBAUER WITOLD A; ZUCCOLLO ADRIANA; CATANZARO ORLANDO L
权利人:UNIV SHERBROOKE; REGOLI DOMENICO; PLANTE GERARD E; GOBEIL FERNAND; NEUGEBAUER WITOLD A; ZUCCOLLO ADRIANA; CATANZARO ORLANDO L
摘要:The present invention relates to novel antagonists to a B1-bradykinin (B1-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B1 receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B1-BK receptors in these two models. B1-BK antagonists abolished the vasocontraction induced by B1-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B1-antagonists are useful for treating any condition wherein B1-receptor is expressed, particularly during inflammation, and more particularly wherein B1-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B1-receptor.

专利号:US-7041785-B1
优先权日:1996-08-19
标题 :B1-bradykinin receptor antagonists and use thereof
发明人：REGOLI DOMENICO; PLANTE GERARD E; GOBEIL FERNAND; NEUGEBAUER WITOLD A; ZUCOLLO ADRIANA; CATANZARO ORLANDO L
权利人:UNIV SHERBROOKE
摘要:The present invention relates to novel antagonists to a B 1 -bradykinin (B 1 -BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B 1 receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B 1 -BK receptors in these two models. B 1 -BK antagonists abolished the vasocontraction induced by B 1 -BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B 1 -antagonists are useful for treating any condition wherein B 1 -receptor is expressed, particularly during inflammation, and more particularly wherein B 1 -receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B 1 -receptor.